Price
$2.07
Decreased by -0.96%
Dollar volume (20D)
13.29 M
ADR%
12.37
Earnings report date
Nov 7, 2025
Shares float
45.41 M
Shares short
14.38 M [31.68%]
Shares outstanding
124.96 M
Market cap
272.41 M
Beta
2.06
Price/earnings
N/A
20D range
1.92 2.84
50D range
0.17 3.29
200D range
0.13 3.29

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company.

The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers.

It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant.

The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML.

It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies.

The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 7, 25 0.00
Increased by +100.00%
-0.22
Increased by +100.00%
May 7, 25 -0.26
Increased by +42.22%
-0.21
Decreased by -25.00%
Mar 18, 25 -0.44
Decreased by -12.82%
-0.31
Decreased by -43.46%
Nov 5, 24 -0.40
Increased by +18.37%
-0.40
Aug 8, 24 -0.41
Increased by +8.89%
-0.42
Increased by +2.38%
May 9, 24 -0.45
Decreased by -4.65%
-0.38
Decreased by -18.42%
Mar 20, 24 -0.39
Increased by +25.00%
-0.50
Increased by +22.00%
Nov 7, 23 -0.49
Increased by +22.22%
-0.47
Decreased by -4.26%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 0.00
Decreased by N/A%
-32.49 M
Decreased by -5.46%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Decreased by -100.00%
-30.71 M
Decreased by -16.95%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-27.56 M
Increased by +16.97%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-27.84 M
Increased by +7.14%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-30.80 M
Decreased by -16.49%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 12.23 M
Increased by +N/A%
-26.26 M
Decreased by -14.68%
Decreased by -214.80%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-33.19 M
Decreased by -41.38%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-29.98 M
Decreased by -39.27%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY